Vaccine Development

The field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials. Developing safe and effective vaccines requires a clear understanding of early immune responses at the injection site. Skin-resident innate immune cells play a key role in antigen sensing, processing, and adaptive immunity initiation, yet traditional non-clinical models often fail to replicate human immune responses. To address this challenge, Genoskin’s VaxSkin^® platform provides a human-relevant, ex vivo skin-based workflow for high-resolution immunogenicity studies. This study highlights how VaxSkin^® advances vaccine research, offering a scalable, reproducible, and ethically responsible approach to assessing vaccine-induced immune responses in human skin.

This application note highlights the power of Genoskin’s VaxSkin^® platform in studying vaccine immunogenicity. Using the mRNA1273 COVID-19 vaccine (Moderna) as a model immunogenic drug, we demonstrate how VaxSkin^® enables a comprehensive analysis of the biological response to vaccination at both the organ and single-cell levels. In the context of drug and vaccine discovery and development, VaxSkin^® serves as a powerful tool for:

• Deciphering molecular mechanisms of action
• Prioritizing lead candidates
• Assessing toxicity and safety
• Identifying biomarkers for immune response profiling.

By bridging the gap between non-clinical models and human immune responses, VaxSkin^® provides a unique, translational approach to accelerate vaccine research and optimize immunogenicity assessment.

After submitting this form, you will receive an email with the link to access our application note.